A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Schnitzbauer, Andreas A ^a   Zuelke, Carl ^a   Graeb, Christian ^b   Rochon, Justine ^a   Bilbao, Itxarone ^c   Burra, Patrizia ^d   de Jong, Koert P ^e   Duvoux, Christophe ^f   Kneteman, Norman M ^g   Adam, Rene ^h,at   Bechstein, Wolf O ⁱ   Becker, Thomas ^j   Beckebaum, Susanne ^k   Chazouillères, Olivier ^l   Cillo, Umberto ^d   Colledan, Michele ^m   Fändrich, Fred ⁿ   Gugenheim, Jean ^o   Hauss, Johann P ^p   Heise, Michael ^q   Hidalgo, Ernest ^r   Jamieson, Neville ^s   Königsrainer, Alfred ^t   Lamby, Philipp E ^a   Lerut, Jan P ^u   Mäkisalo, Heikki ^v   Margreiter, Raimund ^w   Mazzaferro, Vincenzo ^x   Mutzbauer, Ingrid ^a   Otto, Gerd ^y   Pageaux, Georges Philippe ^z   Pinna, Antonio D ^aa   Pirenne, Jacques ^ab   Rizell, Magnus ^ac   Rossi, Giorgio ^ad   Rostaing, Lionel ^ae   Roy, Andre ^af   Turrion, Victor S ^ag   Schmidt, Jan ^ah   Troisi, Roberto I ^ai   van Hoek, Bart ^aj   Valente, Umberto ^ak   Wolf, Philippe ^al   Wolters, Heiner ^am   Mirza, Darius F ^an   Scholz, Tim ^ao   Steininger, Rudolf ^ap   Soderdahl, Gunnar ^aq   Strasser, Simone I ^ar   Jauch, Karl Walter ^b   Neuhaus, Peter ^as   Schlitt, Hans J ^a   Geissler, Edward K ^a   more..

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITY OF ALBERTA   (Canada)

^h HÔPITAL PAUL BROUSSE   (France)

ⁱ GOETHE UNIVERSITY   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l SORBONNE UNIVERSITÉ   (France)

^m OSPEDALI RIUNITI   (Italy)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^p UNIVERSITY OF LEIPZIG   (Germany)

^q FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^r ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^s ADDENBROOKE S HOSPITAL   (United Kingdom)

^t UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^u UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^v HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^w INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^x NATIONAL CANCER INSTITUTE   (Italy)

^y JOHANNES GUTENBERG UNIVERSITY   (Germany)

^z HÔPITAL SAINT ELOI   (France)

^aa UNIVERSITY OF BOLOGNA   (Italy)

^ab UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ac SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ad FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^ae TOULOUSE UNIVERSITY HOSPITAL   (France)

^af UNIVERSITY OF MONTREAL   (Canada)

^ag HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^ah UNIVERSITY OF HEIDELBERG   (Germany)

^ai GHENT UNIVERSITY HOSPITAL   (Belgium)

^aj LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ak UNIVERSITY OF GENOA   (Italy)

^al HÔPITAL DE HAUTEPIERRE   (France)

^am UNIVERSITY OF MÜNSTER   (Germany)

^an QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^ao OSLO UNIVERSITY HOSPITAL   (Norway)

^ap MEDICAL UNIVERSITY OF VIENNA   (Austria)

^aq KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ar ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^as CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^at UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SURGICAL PATIENT; TUMOR RECURRENCE; TUMOR VOLUME; ALLOTRANSPLANTATION; AUSTRALIA; CANADA; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; EUROPE; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; TIME; TREATMENT OUTCOME;

AUSTRALIA; CANADA; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; RECURRENCE; RISK FACTORS; SIROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77954043183     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-190     Document Type: Article

References (21)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699. 10.1056/NEJM199603143341104, 8594428.
2. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534. 10.1038/17401, 10028970.
3. Koehl G, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004, 77:1319-1326. 10.1097/00007890-200405150-00002, 15167584.
4. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135. 10.1038/nm0202-128, 11821896.
5. Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001, 137:14-20. 10.1067/mlc.2001.111469, 11150019.
6. Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999, 67:510-513. 10.1097/00007890-199902270-00003, 10071018.
7. Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002, 34:1392-1393. 10.1016/S0041-1345(02)02899-3, 12176410.
8. Geissler EK, Schlitt HJ, Thomas G. mTOR, Cancer and Transplantation. Am J Transplant 2008, 8:2212-2218. 10.1111/j.1600-6143.2008.02391.x, 18785960.
9. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002, 73:1565-1572. 10.1097/00007890-200205270-00008, 12042641.
10. Bjornsti MA, Houghton PJ. The tor pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348. 10.1038/nrc1362, 15122205.
11. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998, 29:986-991. 10.1016/S0046-8177(98)90205-2, 9744316.
12. Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, et al. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 2009, 49:523-532. 10.1002/hep.22685, 19085954.
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281. 10.1056/NEJMoa066838, 17538086.
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228.
15. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889. 10.1097/01.TP.0000184006.43152.8D, 16249734.
16. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006, 17:581-589. 10.1681/ASN.2005090993, 16434506.
17. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004, 10:1301-1311. 10.1002/lt.20237, 15376305.
18. Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007, 83:1162-1168. 10.1097/01.tp.0000262607.95372.e0, 17496530.
19. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008, 14:633-638. 10.1002/lt.21420, 18324656.
20. Schnitzbauer AA, Lamby PE, Mutzbauer I, Zuelke C, Schlitt HJ, Geissler EK. Procedures for ethical review for clinical trials within the EU. BMJ 2009, 338:b1893. 10.1136/bmj.b1893, 19465471.
21. Heimbach JK. Liver transplantation for hepatocellular carcinoma. The Cancer Journal 2008, 14:95-99. 10.1097/PPO.0b013e31816a0f6f, 18391614.